Manuscripts and Publications

Filters: Keyword is Antiretroviral Therapy, Highly Active  [Clear All Filters]
2018
Mullins TLKowalczy, Li SX, Bethel J, Goodenow MM, Hudey S, Sleasman JW.  2018.  Sexually transmitted infections and immune activation among HIV-infected but virally suppressed youth on antiretroviral therapy.. J Clin Virol. 102:7-11.
Williams JC, Zhang X, Karki M, Chi Y-Y, Wallet SM, Rudy BJ, Nichols SL, Goodenow MM, Sleasman JW.  2018.  Soluble CD14, CD163, and CD27 biomarkers distinguish ART-suppressed youth living with HIV from healthy controls.. J Leukoc Biol. 103(4):671-680.
Havens PL, Long D, Schuster GU, Gordon CM, Price G, Wilson CM, Kapogiannis BG, Mulligan K, Stephensen CB.  2018.  Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.. Antivir Ther. 23(7):623-628.
2016
Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, E Patton D, Ren W, Thornton SE, Major-Wilson HO, Puga AM et al..  2016.  Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.. J Neurovirol. 22(2):218-30.
Ruan A, Tobin NH, Mulligan K, Rollie A, Li F, Sleasman J, Aldrovandi GM.  2016.  Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021.. J Acquir Immune Defic Syndr. 72(4):372-5.
MacDonell KKolmodin, Jacques-Tiura AJ, Naar S, Fernandez MIsabella.  2016.  Predictors of Self-Reported Adherence to Antiretroviral Medication in a Multisite Study of Ethnic and Racial Minority HIV-Positive Youth.. J Pediatr Psychol. 41(4):419-28.
2015
Havens PL, Hazra R.  2015.  Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy.. Pediatr Infect Dis J. 34(4):406-8.
Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G et al..  2015.  Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061.. J Acquir Immune Defic Syndr. 69(1):52-60.
2013
MacDonell K, Naar-King S, Huszti H, Belzer M.  2013.  Barriers to medication adherence in behaviorally and perinatally infected youth living with HIV.. AIDS Behav. 17(1):86-93.
Nichols SL, Bethel J, Garvie PA, Patton DE, Thornton S, Kapogiannis BG, Ren W, Major-Wilson H, Puga A, Woods SP.  2013.  Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.. J Adolesc Health. 53(6):763-71.
2012
Mulligan K, D Harris R, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, Monte D, Sleasman J, Wilson CM, Aldrovandi GM.  2012.  Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B.. Clin Infect Dis. 55(3):461-8.
Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, Bethel J, Pan CG, Woodhouse LR, Van Loan MD et al..  2012.  Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.. Clin Infect Dis. 54(7):1013-25.
2011
M Fernández I, Hosek S, Warren JC, Jacobs RJ, Hernandez N, Martinez J.  2011.  Development of an easy to use tool to assess HIV treatment readiness in adolescent clinical care settings.. AIDS Care. 23(11):1492-9.
2010
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2010.  Prevalence and interactions of patient-related risks for nonadherence to antiretroviral therapy among perinatally infected youth in the United States.. AIDS Patient Care STDS. 24(2):97-104.
2009
Rudy BJ, Murphy DA, D Harris R, Muenz L, Ellen J.  2009.  Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions.. AIDS Patient Care STDS. 23(3):185-94.
Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK.  2009.  Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression.. AIDS Res Hum Retroviruses. 25(6):555-61.